
|Articles|April 1, 2007
Oncology NEWS International
- Oncology NEWS International Vol 16 No 4
- Volume 16
- Issue 4
Updated Varian Brachytherapy Applicator Receives Clearance
Updated Varian Brachytherapy Applicator Receives Clearance
Advertisement
PALO ALTO, CaliforniaFDA has granted Varian Medical Systems 510K clearance to market its Esophagus Bougie Set, a brachytherapy applicator designed specifically for intraluminal treatment of esophageal cancer. According to Varian, the new technology allows optimal positioning of the applicator set in reference to the tissue being treated and can be used with Varian's full range of VariSoruce and GammaMed HDR afterloaders.
Articles in this issue
over 19 years ago
Curcumin Evaluated for the Treatment of Pancreatic Cancerover 19 years ago
Tykerb Approved for Metastatic HER2+ Breast Cancerover 19 years ago
Drug for BPH May Also Reduce the Risk of Prostate Cancerover 19 years ago
Phase III Trial of Prostvac-VF Is Launchedover 19 years ago
Electronic System Reminds Patients to Schedule Examsover 19 years ago
Phase II Trial of Panzem for Renal Cell Carcinoma Initiatedover 19 years ago
Chemotherapy May Enrich Tumorigenic Cells in Breast Caover 19 years ago
Watchful Waiting Management for Prostate Ca a Hard SellAdvertisement
Related to this article

Data from the OrigAMI-4 trial support the accelerated approval of amivantamab and hyaluronidase-lpuj for this HNSCC population.

An NDA submission had been completed for zipalertinib plus chemotherapy in untreated EGFR exon 20 insertion–mutant NSCLC based on REZILIENT3 data.

The FDA approved giredestrant plus everolimus for ER-positive, HER2-negative, ESR1-mutated breast cancer based on data from the phase 3 evERA trial.

Martin Gleave, CM, MD, FRCSC, FACS, discussed perioperative therapy selection, the GUNS trial, and postoperative radiotherapy in prostate cancer.

In OptimUM-01, darovasertib plus crizotinib produced a 34.1% ORR and 21.1-month median OS in untreated metastatic uveal melanoma, regardless of HLA status.

Qingqing Cai, MD, PhD, discussed early efficacy data for rocbrutinib plus R-CHOP in untreated non-GCB DLBCL and how they compare with frontMIND at ESMO 2026.

The CHMP recommended belzutifan plus lenvatinib for advanced clear cell RCC after anti–PD-(L)1 therapy, based on phase 3 LITESPARK-011 data.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Giredestrant/Everolimus for ER+, HER2–, ESR1-Mutated Breast Cancer
2
Who Benefits Most From Perioperative Therapy in High-Risk Prostate Cancer?
3
Cretostimogene Cuts Recurrence Risk in Intermediate-Risk, High-Grade Ta NMIBC
4
Belzutifan Plus Lenvatinib Earns Positive CHMP Opinion in Advanced ccRCC
5

